nmdp logo

Cryopreserved or Fresh AlloHCT Graft Lessons Learned from the COVID19 Pandemic

May 25, 2023


At the start of the COVID-19 pandemic, most global donor registries mandated cryopreservation of products for allogeneic hematopoietic cell transplantation (alloHCT) to ensure patient safety and the timeliness of care delivery. During this webinar, expert panelists share research findings from the COVID-19 pandemic that provide a deeper understanding of the impact of graft cryopreservation on alloHCT patient outcomes.

Two transplant center physician panelists discuss use cases for cryopreservation, how their selection strategies have evolved since the pandemic and their process for choosing cryopreserved versus fresh grafts for alloHCT.

Watch the on-demand webinar

Learning Objectives 

  • Recent research on the impacts of using cryopreserved grafts in alloHCT
  • Lessons learned about cryopreservation during the COVID-19 pandemic
  • Current and evolving transplant center use cases for selecting cryopreserved vs. fresh grafts 
  • Considerations for transplant clinical decision making and protocols related to cryopreservation 

Target Audience 

Coordinators, physicians, medical directors and BMT fellows at transplant centers; HLA lab directors


Steven Devine, MD (moderator)

Chief Medical Officer, NMDP

Senior Scientific Director


Heather Stefanski, MD, PhD

Vice President of Medical Services


Alexandra Gomez Arteaga, MD

Assistant Professor of Medicine in the Division of Hematology and Medical Oncology

Weill Cornell Medicine/New York-Presbyterian Hospital

Taiga Nishihori, MD

Senior Member; Medical Director — BMT Program

Moffitt Cancer Center